迈得医疗(688310) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥72,708,646.44, representing a year-on-year increase of 39.83%[5] - The net profit attributable to shareholders for Q1 2023 was ¥13,411,992.23, showing a significant increase of 457.73% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥11,384,381.02, reflecting a year-on-year growth of 661.69%[5] - Basic earnings per share for Q1 2023 were ¥0.16, up 433.33% from the previous year[6] - Net profit for Q1 2023 was ¥15,623,627.82, significantly higher than ¥2,205,325.56 in Q1 2022, marking a 608.5% increase[20] - Earnings per share for Q1 2023 were ¥0.16, compared to ¥0.03 in Q1 2022, indicating a substantial growth in profitability[21] - The company reported a significant increase in other income, which rose to ¥7,289,577.72 in Q1 2023 from ¥2,998,548.72 in Q1 2022, a growth of 143.5%[19] Cash Flow - The net cash flow from operating activities reached ¥42,615,106.97, marking an increase of 275.36% year-on-year[6] - Cash inflow from operating activities in Q1 2023 totaled ¥144,638,732.58, compared to ¥37,736,410.50 in Q1 2022, representing a 284.5% increase[21] - Cash outflow from operating activities for Q1 2023 was ¥102,023,625.61, up from ¥62,038,188.52 in Q1 2022, reflecting a 64.5% increase[21] - Net cash flow from operating activities was $42,615,106.97, a decrease of $24,301,778.02 compared to the previous period[22] - Net cash flow from investing activities was -$54,165,252.47, compared to -$11,227,276.47 in the previous period[22] - Cash and cash equivalents at the end of the period totaled $209,923,467.15, down from $278,858,739.67 in the previous period[22] - The company reported a net decrease in cash and cash equivalents of $11,928,400.16, compared to a decrease of $35,982,912.71 in the previous period[22] - The cash inflow from investment activities was $70,195,000.00, while cash outflow was $81,422,276.47[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,087,370,320.57, an increase of 4.73% from the end of the previous year[6] - The total assets as of March 31, 2023, amounted to CNY 1,087,370,320.57, an increase from CNY 1,038,260,721.13 as of December 31, 2022, reflecting a growth of approximately 4.0%[15] - The total current assets increased to CNY 678,446,600.29 from CNY 635,880,464.58, representing a growth of about 6.3%[16] - The cash and cash equivalents decreased slightly to CNY 217,751,592.74 from CNY 224,946,034.81, a decline of approximately 3.0%[15] - The accounts receivable rose to CNY 122,233,542.63 from CNY 121,053,391.62, indicating a marginal increase of about 1.0%[16] - The inventory increased significantly to CNY 150,655,144.93 from CNY 116,579,561.59, marking an increase of approximately 28.2%[16] - The total non-current assets amounted to CNY 408,923,720.28, up from CNY 402,380,256.55, showing a growth of about 1.3%[16] - The total liabilities increased to CNY 1,087,370,320.57, reflecting a rise from the previous period, indicating a potential increase in leverage[16] - The company reported a significant increase in contract liabilities to CNY 76,102,851.10 from CNY 60,047,730.38, which is an increase of approximately 26.7%[16] - The company's total liabilities as of Q1 2023 amounted to ¥240,000,349.11, compared to ¥208,658,267.53 in Q1 2022, an increase of 15.0%[18] - Total equity for Q1 2023 was ¥847,369,971.46, up from ¥829,602,453.60 in Q1 2022, indicating a growth of 2.1%[18] Research and Development - Research and development expenses totaled ¥7,517,084.03, which is a decrease of 14.08% year-on-year, accounting for 10.34% of operating revenue[6] - Research and development expenses for Q1 2023 were ¥7,517,084.03, slightly down from ¥8,748,981.09 in Q1 2022, a decrease of 14.1%[19] Shareholder Information - The company reported a total of 3,300 common shareholders at the end of the reporting period[10] - The top shareholder, Lin Junhua, holds 39,986,000 shares, representing 47.66% of the total shares[11] Other Information - The company has not disclosed any new product developments or market expansion strategies in this report[14] - There are no significant changes in shareholder relationships or financing activities reported during this period[13] - The company did not apply new accounting standards for the first quarter of 2023[23]